Search results
Added:
1 month ago
Added:
1 month ago
Added:
2 months ago
AHA Scientific Sessions 2025 – Dr Anna Meta Dyrvig Kristensen (Copenhagen University Hospital, Bispebjerg and Frederiksberg, DK) presents an individual patient data meta-analysis examining beta-blocker therapy after myocardial infarction in patients with preserved left ventricular ejection fraction.This comprehensive meta-analysis pooled individual patient data from five randomized controlled…
View more
Added:
2 months ago
Start date:
Jul 02, 2025
.img-row:after {
content: "";
clear: both;
display: table;
}
.img-column {
float: left;
width: 50%;
padding: 5px;
}
@media screen and (max-width: 500px) {
.img-column {
width: 100%;
}
}
Join James Burton (University of Leicester, Leicester, UK), Clara Bonanad (University Clinical Hospital of Valencia, Valencia, ES), Aaron Wong (Princess of Wales Hospital, Bridgend, Wales, UK)…
View more
Added:
3 months ago
Learn about the definition and implications of a shock diagnosis and systems of care and the role of the shock team from Dr Frederick Welt (University of Utah, US).This three-part video lecture series, part of Women As One’s CLIMB® 2025 Skills Training Programme, offers case-based insights into Coronary and Mechanical Support for Cardiogenic Shock, curated by Dr Alison Duncan and Dr Frederick…
View more
Added:
4 months ago
ESC Congress 2025 - Dr Muthiah Vaduganathan (Brigham and Women’s Hospital, Boston, US) joins us to discuss findings from a trial investigating the lifetime benefits of combination therapy for patients with HFpEF by looking at individual level data from DELIVER, FINEARTS-HF and PARAGON-HF trials.Interview Questions:1. What is the reasoning behind the trial?2. What was the study design and patient…
View more
Added:
5 months ago
Added:
8 months ago
Added:
3 months ago
EASD Congress 2025 - Dr Camilla Andersen (The University of Western Australia, Perth, AU) joins us to discuss findings from the EMPIRE-PREVENT: Metabolic study, investigating the metabolic effects of empagliflozin in elderly and obese patients at high risk of developing heart failure (HF).This randomized controlled trial evaluated 165 patients aged 60–84 years with obesity (BMI >28kg/m²) and…
View more